United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$332Mraised across 6 rounds since 2009, from 6 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Reported by fiercebiotech.com
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
New Enterprise Associates
Kleiner Perkins Caufield & Byers
MPM Capital
Bay City CapitalAmgenCelgene
Astellas Venture Management
GlaxoSmithKlineRoyalty Pharma
Leukemia & Lymphoma SocietyFrom historical deal records. Wrong? Tell us.
Missing a round, or an investor who was in one? Tell us.
Epizyme's investors include New Enterprise Associates, Kleiner Perkins Caufield & Byers, MPM Capital, Bay City Capital and Amgen, and 6 more on record.
Epizyme has raised $332M across 6 rounds since 2009.
Epizyme's most recent round was an Undisclosed round of $270M in Nov 2019.
Its most recent round, $270M in Nov 2019, is also its largest on record.
Epizyme's first round on record, in Oct 2009, was backed by Kleiner Perkins Caufield & Byers, MPM Capital and Bay City Capital and 2 others.
Epizyme's latest named round is an Undisclosed round, in Nov 2019.
Epizyme is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
